PREMIUM SEARCH Search by job title, geography and build a list of executive contacts
Goldman Sachs added Alcon (ACL
) to its recommended list; the stock was previously rated market outperform.
Analyst Katherine Breeds says Alcon represents an attractive investment opportunity. She notes the company earns strong marks when assessed on a relative basis to other specialty pharmaceutical companies in her universe based on industry metrics, value creation and earnings per share quality.
She raised her $1.55 2002 earnings per share estimate to $1.56, and upped the $1.71 2003 earnings per share estimate to $1.79.
Any advice, analysis, or recommendations contained in articles labeled "Insight from Standard & Poor's" reflect the views of Standard & Poor's, which operates separately from and independently of BusinessWeek Online. It is possible that BWOL may from time to time publish information that is not consistent with advice, analysis, or recommendations that are published by Standard & Poor's. Standard & Poor's and BusinessWeek Online are each units of The McGraw-Hill Companies, Inc.
Get BusinessWeek directly on your desktop with our RSS feeds.
Add BusinessWeek news to your Web site with our headline feed.
Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.
To subscribe online to BusinessWeek magazine, please click here.
Copyright 2002, Bloomberg L.P.
Printer-Friendly Version
